Specifically, simulations indicate that anti-PD-1 treatments administered Q3Dx3 induced a maximum increase of 2.8% in CTL concentration and 0.017% reduction in tumor volume 10 days after treatment initiation compared to control simulations, whereas anti-PD-L1 treatment administered Q3Dx3 induced a maximum increase of 56% in CTL concentration and 52% reduction in tumor volume (Figures 1C,D). The gene discussed is PDCD1; the disease is neoplasm.